An interventional study of Single-Layer Locked Uterine Closure and Double-Layer Incision-Parallel Nonlocking Uterine Closure in Cesarean Scar Defect (Isthmococele), sponsored by Onur Karaaslan. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Onur Karaaslan · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Cicatrix with a site in Turkey — 4 open to participants now, 4 under way, none of them phase 3. Cicatrix · Turkey.
Among the 18 studies in Cicatrix with a site in Turkey, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 14 with no phase, and was the 18th registered.
616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.
Browse Cicatrix studies →4 of the 18 studies in Cicatrix with a site in Turkey are open now. Recruiting first, the newest first:
Başakşehir Çam & Sakura City Hospital · Sites in Turkey
Ages 17–60 · Women only
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–44 · Women only · Healthy volunteers
Ardahan University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Dr. Lutfi Kirdar Kartal Training and Research Hospital · Sites in Turkey
Ages 40–60
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2024.
This study's enrollment of 60 is above the median of 40 across 515 interventional studies indexed under Cicatrix.
Median enrollment 95 across the 14 interventional studies, 170 across the 4 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Onur Karaaslan as lead sponsor.
Onur Karaaslan has 1 study filed under Cicatrix — fewer than ten, so there is no comparison to draw.
1 of the studies in Cicatrix with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07791953Dr. Lutfi Kirdar Kartal Training and Research HospitalEffect of an Intraoperative Polynucleotide Injection on Scar Quality After Thyroidectomy | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Cicatrix with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial was conducted to compare two uterine closure techniques in women undergoing primary cesarean delivery. The study evaluated whether the technique used to close the uterine incision affects the development and characteristics of cesarean scar defects (CSD).
Participants were randomly assigned in a 1:1 ratio to either a conventional single-layer locked continuous uterine closure technique or a double-layer, incision-parallel, nonlocking continuous closure technique. Cesarean scar healing was evaluated at least three months after delivery using transvaginal ultrasonography. The primary outcome was the presence of a cesarean scar defect. Additional ultrasound measurements were used to evaluate the morphology of the cesarean scar and residual myometrial thickness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 18-45 years Undergoing first cesarean delivery Early-term, term, or post-term pregnancy Elective or emergency indication for cesarean delivery Provided written
Exclusion Criteria:
Previous cesarean delivery Congenital uterine anomaly Chronic anemia Uncontrolled gestational or pregestational diabetes mellitus Uncontrolled hypertension Severe preeclampsia >30 kg/m² Active labor lasting >5 hours Cervical dilatation >5 cm at cesarean delivery
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants underwent uterine incision closure using a single-layer locked continuous suturing technique.
Procedure: Single-Layer Locked Uterine Closure
Participants underwent uterine incision closure using a double-layer, incision-parallel, nonlocking continuous suturing technique.
Procedure: Double-Layer Incision-Parallel Nonlocking Uterine Closure
Uterine closure was performed using a single-layer locked continuous suturing technique after cesarean delivery.
Uterine closure was performed using a double-layer, incision-parallel, continuous nonlocking suturing technique. Primary corner sutures were placed at both ends of the uterine incision. In the first layer, the lower-segment myometrium was approximated with full-thickness nonlocking sutures placed parallel to the incision, with corresponding bites taken from the upper segment at the same level. The second layer consisted of continuous nonlocking approximation of the serosal-subserosal tissue.
Incidence of Cesarean Scar Defect
Cesarean scar defect (CSD) was assessed by transvaginal ultrasonography and defined as a visible hypoechoic indentation at the site of the cesarean scar with a depth of at least 2 mm.
Time frame: At least 3 months after cesarean delivery
Cesarean Scar Morphometric Measurements
Cesarean scar morphology was assessed by transvaginal ultrasonography. Measurements included scar indentation depth and length, residual myometrial thickness (RMT), adjacent myometrial thickness (AMT), uterovesical fold distance, vesicovaginal fold distance, and the distance between the scar indentation and the external cervical os. Measurements were expressed in millimeters. Scar indentation morphology was also recorded. When no indentation was visible, indentation depth and length were recorded as 0 mm, and external os distance was considered not applicable.
Time frame: At least 3 months after cesarean delivery
Perioperative Hemoglobin Change
Hemoglobin levels were measured preoperatively and on postoperative day 1. Hemoglobin reduction was calculated as the preoperative hemoglobin value minus the postoperative day-1 value and was expressed in g/dL.
Time frame: From preoperative assessment to postoperative day 1.
Self-Reported Postpartum Symptoms
Self-reported symptoms were categorized as no symptoms, pain-related symptoms, dyspareunia, abnormal bleeding or spotting, and other postoperative symptoms.
Time frame: At least 3 months after cesarean delivery
Plan to share: No — Individual participant data will not be publicly shared due to participant confidentiality and ethical considerations.
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Feb 2025, 7 months.
Of 175 non-industry interventional studies with no phase under Cicatrix, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's 7 months is below that.
Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 8 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.